This move comes as a result of the Gateway(R) Technology open architecture licensing policy. Under the Gateway(R) Technology open architecture, academic and government researchers that purchase the system will be able to create and distribute clones within the scientific community.
“The ability to include Invitrogen's Gateway(R) technology adds versatility to the genes captured in the Mammalian Gene Collection program”
"The ability to include Invitrogen's Gateway(R) technology adds versatility to the genes captured in the Mammalian Gene Collection program," said Francis S. Collins, M.D., Ph.D., Director of the NHGRI. "We are gratified that the leaders of Invitrogen have decided to share these resources, which will benefit researchers all over the world."
Gateway(R) Technology is a method for cloning DNA sequences in order to study their function. Some Gateway(R) vectors allow the synthesis of the protein product. Since proteins require different cellular host systems to show their effects, Gateway(R) Technology makes transitioning in and out of these systems effortless, enabling researchers to move their experiments along rapidly, with great consistency.
"Because Gateway(R) is such a wide-reaching application for life science research, we felt it was vital to develop a policy that encouraged sweeping collaboration," said Invitrogen Chief Scientist, Dr. John Carrino. "Scientists working in areas from gene and protein research to furthering emerging technologies, such as RNA interference and software simulated cloning, can benefit from the shared resources Gateway(R) offers."
In November 2003, Invitrogen announced that it was amending its licensing policies around its Gateway(R) Technology to facilitate the distribution of materials containing Gateway(R) Technology created in government and academic research. The Gateway(R) Technology open architecture allows government and academic researchers to create and distribute Gateway(R) entry clones and expression clones to any entity, without royalties or licensing fees. Other organizations may obtain a license to distribute such clones on behalf of academic and government researchers, subject to a nominal fee of $10 per Gateway(R) expression clone.
"We are delighted to work with the NIH in our shared goal of creating a comprehensive repository of genomic information to accelerate life science research," said Gregory T. Lucier, President and CEO of Invitrogen. "At Invitrogen, we continue to pursue ways to champion the breakthrough science being conducted by our customers with the goal of making the research process more consistent, effective and efficient."
For more information about Gateway(R) Technology, visit www.invitrogen.com/gateway/.
About the Mammalian Gene Collection
The Mammalian Gene Collection program is an NIH-funded effort to generate a publicly available resource of sequenced full-length cDNAs for all human and mouse genes and a set of rat genes. This program includes constructing new cDNA libraries, screening clones by EST generation to identify those containing putative full-length cDNAs, determining the complete sequence of candidate full-length clones, and establishing repository and distribution systems for the resulting clone collections. To get at clones not readily accessible by the EST-based strategy, the MGC program has recently added a gene-specific, targeted approach to find clones not yet in the collection.
About Invitrogen
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 3,800 scientists and other professionals. For more information about Invitrogen visit the company's web site at www.invitrogen.com
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to statements that: 1) Gateway Technology will add versatility to the genes captured in the Mammalian Gene Collection program; 2) Gateway Technology's Open Architecture will benefit researchers all over the world; 3) Researchers working in gene and protein research, RNA Interference and software simulated cloning can all benefit from Gateway's shared resources. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that: a) Gateway Technology, while providing an advanced cloning system, may not provide additional versatility to the MGC clones; b) Gateway Technology's Open Architecture may not be widely adopted globally; c) Researchers in specific areas may not find Gateway Technology superior to current methods of cloning, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
